Effects of high-flow nasal cannula in patients with mild to moderate hypercapnia: a prospective observational study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Evidence for using high-flow nasal cannula (HFNC) in hypercapnia is still limited. Most of the clinical studies had been conducted retrospectively, and there had been conflicting reports for the effects of HFNC on hypercapnia correction in prospective studies. Therefore, more evidence is needed to understand the effect of the HFNC in hypercapnia. Methods: We conducted a multicenter prospective observational study after applying HFNC to 45 hospitalized subjects who had moderate hypercapnia (arterial partial pressure of carbon dioxide [PaCO2], 43–70 mm Hg) without severe respiratory acidosis (pH <7.30). The primary outcome was a change in PaCO2 level in the first 24 hours of HFNC use. The secondary outcomes were changes in other parameters of arterial blood gas analysis, changes in respiration rates, and clinical outcomes. Results: There was a significant decrease in PaCO2 in the first hour of HFNC application (-3.80 mm Hg; 95% confidence interval, -6.35 to -1.24; P<0.001). Reduction of PaCO2 was more prominent in subjects who did not have underlying obstructive lung disease. There was a correction in pH, but no significant changes in respiratory rate, bicarbonate, and arterial partial pressure of oxygen/fraction of inspired oxygen ratio. Mechanical ventilation was not required for 93.3% (42/45) of our study population. Conclusions: We suggest that HFNC could be a safe alternative for oxygen delivery in hypercapnia patients who do not need immediate mechanical ventilation. With HFNC oxygenation, correction of hypercapnia could be expected, especially in patients who do not have obstructive lung diseases
Abstract
Background: Evidence for using high-flow nasal cannula (HFNC) in hypercapnia is still limited. Most of the clinical studies had been conducted retrospectively, and there had been conflicting reports for the effects of HFNC on hypercapnia correction in prospective studies. Therefore, more evidence is needed to understand the effect of the HFNC in hypercapnia. Methods: We conducted a multicenter prospective observational study after applying HFNC to 45 hospitalized subjects who had moderate hypercapnia (arterial partial pressure of carbon dioxide [PaCO2], 43–70 mm Hg) without severe respiratory acidosis (pH <7.30). The primary outcome was a change in PaCO2 level in the first 24 hours of HFNC use. The secondary outcomes were changes in other parameters of arterial blood gas analysis, changes in respiration rates, and clinical outcomes. Results: There was a significant decrease in PaCO2 in the first hour of HFNC application (-3.80 mm Hg; 95% confidence interval, -6.35 to -1.24; P<0.001). Reduction of PaCO2 was more prominent in subjects who did not have underlying obstructive lung disease. There was a correction in pH, but no significant changes in respiratory rate, bicarbonate, and arterial partial pressure of oxygen/fraction of inspired oxygen ratio. Mechanical ventilation was not required for 93.3% (42/45) of our study population. Conclusions: We suggest that HFNC could be a safe alternative for oxygen delivery in hypercapnia patients who do not need immediate mechanical ventilation. With HFNC oxygenation, correction of hypercapnia could be expected, especially in patients who do not have obstructive lung diseases
참고문헌 (16)
- Drake MG, "High-flow nasal cannula oxygen in adults : an evidence-based assessment", Ann Am Thorac Soc, 15, pp.145~155 (2018)
- Möller W, "Nasal high flow clears anatomical dead space in upper airway models", J Appl Physiol(1985), 118, pp.1525~1532 (2015)
- Bräunlich J, "Nasal highflow eliminates CO2 from lower airways", Respir Physiol Neurobiol, 242, pp.86~88 (2017)
- Biselli PJ, "Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls : a prospective observational study", J Appl Physiol(1985), 122, pp.82~88 (2017)
- Patel A, "Transnasal humidified rapid-insufflation ventilatory exchange(THRIVE) : a physiological method of increasing apnoea time in patients with difficult airways", Anaesthesia, 70, pp.323~329 (2015)
- Jeong JH, "Changes in arterial blood gases after use of high-flow nasal cannula therapy in the ED", Am J Emerg Med, 33, pp.1344~1349 (2015)
- Kim ES, "Effectiveness of high-flow nasal cannula oxygen therapy for acute respiratory failure with hypercapnia", J Thorac Dis, 10, pp.882~888 (2018)
- Sztrymf B, "Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure : a prospective observational study", J Crit Care, 27, pp.324~ (2012)
- Frat JP, "High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure", N Engl J Med, 372, pp.2185~2196 (2015)
- Rochwerg B, "High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure : a systematic review and meta-analysis", Intensive Care Med, 45, pp.563~572 (2019)
- Nilius G, "Effects of nasal insufflation on arterial gas exchange and breathing pattern in patients with chronic obstructive pulmonary disease and hypercapnic respiratory failure", Adv Exp Med Biol, 755, pp.27~34 (2013)
- Roussos C, "Respiratory failure", Eur Respir J, 47(Suppl), pp.3s~14s (2003)
- Davidson AC, "BTS", ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults, 2016, pp.71(Suppl 2), ii1~ii35
- Papachatzakis Y, "High-flow oxygen through nasal cannula vs. non-invasive ventilation in hypercapnic respiratory failure: a randomized clinical trial", Int J Environ Res Public Health, 17, pp.5994~ (2020)
- Lee MK, "High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure", Clin Respir J, 12, pp.2046~2056 (2018)
- Huang Y, "High-flow nasal cannula in hypercapnic respiratory failure : a systematic review and meta-analysis", Can Respir J, 2020, pp.7406457~ (2020)